摘要
目的分析探讨贝伐单抗与化疗药物联合用于晚期结直肠癌一线治疗的近期疗效和安全性。方法 20例晚期结直肠癌患者应用贝伐单抗联合5-Fu化疗方案用于治疗晚期结直肠癌,观察其临床疗效、不良反应及疾病进展时间。结果 20例患者中,8例部分缓解(40%),10例稳定(50%),2例进展(10%),客观有效率为40%,疾病控制率为90%,中位疾病进展时间为8.6个月。不良反应轻微,所有患者均可耐受。结论贝伐单抗联合化疗用于晚期结直肠癌的一线治疗效果较好、疾病控制率较高、不增加不良反应。
Objective To observe the effect and security of advanced tumor patients treated by Avastin combined with chemotherapy.Mehhods 20 cases of Advanced Tumor patients treated by Avastin combined with 5-Fu.To observe the clinical efficacy,adverse reactions and disease progression time.Results The cases of PR,SD and PD in 20 patients were 8,10 and 2.RR with the rate of 40%,DCR with the rate of 90%,the TTP was 8.6 months.Adverse effect of mild,all patients can tolerate.Conclusion Avastin combined with chemotherapy for first-line treatment of advanced colorectal cancer is better,disease control rates higher,did not increase the side effects.
出处
《中国医药指南》
2011年第8期190-191,共2页
Guide of China Medicine
关键词
结直肠癌
贝伐单抗
靶向治疗
不良反应
Colorectal cancer
Bevacizumab
Targeted therapy
Adverse effect
